NTLA-2002, an experimental gene-editing therapy for hereditary angioedema (HAE) being developed by Intellia Therapeutics, has been awarded…
Articles by Marisa Wexler, MS
Most hereditary angioedema (HAE) patients in a Phase 1/2 clinical trial have gone months without a swelling attack following…
People with hereditary angioedema (HAE) who switched to Orladeyo (berotralstat) from other preventive treatments generally experience a…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Takeda to extend the approval…
Japan’s Ministry of Health, Labour and Welfare has approved Berinert S.C. Injection 2000 — a C1-inhibitor replacement therapy designed to…
The European Patent Office has granted patent protection to Verseon covering the company’s experimental plasma kallikrein inhibitors (PKIs). Two of…
NTLA-2002, an experimental gene-editing therapy designed to prevent swelling attacks in people with hereditary angioedema (HAE), has been granted…
Protease-activated receptor 1 (PAR1), a protein involved in the regulation of blood vessel permeability or leakage, may contribute to…
Most young children with hereditary angioedema (HAE) in the open-label Phase 3 SPRING study were free of swelling attacks…
Many people with hereditary angioedema (HAE) have non-swelling symptoms, such as rash or fatigue, even when they aren’t having an acute…